$6.00
0.08% yesterday
Nasdaq, Sep 05, 10:00 pm CET
ISIN
US88032L2097
Symbol
TENX

Tenax Therapeutics, Inc. Stock price

$6.00
-0.18 2.84% 1M
-0.24 3.77% 6M
-0.20 3.15% YTD
+2.11 54.11% 1Y
-324.25 98.18% 3Y
-2,346.01 99.75% 5Y
-111,994.01 99.99% 10Y
+5.79 2,754.76% 20Y
Nasdaq, Closing price Fri, Sep 05 2025
-0.01 0.08%
ISIN
US88032L2097
Symbol
TENX
Industry

Key metrics

Basic
Market capitalization
$27.4m
Enterprise Value
$-78.1m
Net debt
positive
Cash
$105.5m
Shares outstanding
4.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
3.9
P/B
0.3
Financial Health
Equity Ratio
95.2%
Return on Equity
-19.1%
ROCE
-33.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | $-24.5m
EBIT
$-35.0m | $-54.8m
Net Income
$-31.5m | $-5.1m
Free Cash Flow
$-19.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -25.9%
EBIT
-168.8% | -180.9%
Net Income
-150.4% | 70.8%
Free Cash Flow
-73.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.8
FCF per Share
$-4.8
Short interest
7.4%
Employees
5
Rev per Employee
$0.0
Show more

Is Tenax Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Tenax Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Tenax Therapeutics, Inc. forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Tenax Therapeutics, Inc. forecast:

Buy
90%
Hold
10%

Financial data from Tenax Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 16 16
195% 195%
-
- Research and Development Expense 20 20
151% 151%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -35 -35
169% 169%
-
Net Profit -31 -31
150% 150%
-

In millions USD.

Don't miss a Thing! We will send you all news about Tenax Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tenax Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
9 days ago
CHAPEL HILL, N.C., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will participate in a fireside chat at the Cantor Global Healthcare Conference 2025, which is taking place fro...
Neutral
GlobeNewsWire
23 days ago
Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026
Neutral
GlobeNewsWire
4 months ago
Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026
More Tenax Therapeutics, Inc. News

Company Profile

Tenax Therapeutics, Inc. engages in the identification, development, and commercialization of novel therapeutic products for the critical care market. Its lead product candidate is Levosimendan, a calcium sensitizer activator for intravenous use in hospitalized patients with acutely decompensated heart failure. The company was founded on May 26, 1967 and is headquartered in Morrisville, NC.

Head office United States
CEO Christopher Giordano
Employees 5
Founded 1967
Website www.tenaxthera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today